New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
09:02 EDTAEZSAeterna Zentaris upgraded to Buy from Hold at MLV Equity
MLV Equity believes Aeterna Zentaris' pipeline drugs, AEZS-108 and AEZS-130, have substantial value and that DSMB recommendation on Perifosine in Q1 could act as a catalysts. Price target is $5.50.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:31 EDTAEZSAeterna Zentaris recruited 500 patients for pivotal Phase 3 ZoptEC study
Subscribe for More Information
June 25, 2015
07:37 EDTAEZSAeterna Zentaris selects Ergomed to conduct Phase 3 clinical trial of Macrilen
Aeterna Zentaris announced that it has executed a definitive agreement with Ergomed, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency.
June 18, 2015
07:32 EDTAEZSAeterna Zentaris awarded extension for NASDAQ listing compliance
Aeterna Zentaris has received notice from NASDAQ determining that the company is eligible for an additional 180 calendar day period, until December 14 to regain compliance with the minimum $1.00 per share required for continued listing. The company's shares continue to trade on the NASDAQ Capital Market under the symbol AEZS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use